Financhill
Sell
25

BTAI Quote, Financials, Valuation and Earnings

Last price:
$1.70
Seasonality move :
-24.29%
Day range:
$1.46 - $1.72
52-week range:
$1.17 - $25.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.75x
P/B ratio:
--
Volume:
193.6K
Avg. volume:
341.7K
1-year change:
-92.29%
Market cap:
$9.4M
Revenue:
$2.3M
EPS (TTM):
-$13.55

Analysts' Opinion

  • Consensus Rating
    BioXcel Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $27.33, BioXcel Therapeutics has an estimated upside of 1652.14% from its current price of $1.69.
  • Price Target Downside
    According to analysts, the lowest downside price target is $16.00 representing 100% downside risk from its current price of $1.69.

Fair Value

  • According to the consensus of 1 analyst, BioXcel Therapeutics has 1652.14% upside to fair value with a price target of $27.33 per share.

BTAI vs. S&P 500

  • Over the past 5 trading days, BioXcel Therapeutics has underperformed the S&P 500 by -14.89% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • BioXcel Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • BioXcel Therapeutics revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter BioXcel Therapeutics reported revenues of $168K.

Earnings Growth

  • BioXcel Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter BioXcel Therapeutics reported earnings per share of -$1.50.
Enterprise value:
84M
EV / Invested capital:
5.47x
Price / LTM sales:
2.75x
EV / EBIT:
--
EV / Revenue:
45.34x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.27x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$226K
Return On Assets:
-73.23%
Net Income Margin (TTM):
-2163.18%
Return On Equity:
--
Return On Invested Capital:
-197.27%
Operating Margin:
-6011.31%
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Income Statement
Revenue -- $1.8M $1.9M $582K $168K
Gross Profit $552K $424K -$226K $502K $154K
Operating Income -$179.4M -$140.6M -$50.7M -$24.2M -$10.1M
EBITDA -$175.2M -$139.2M -$24.2M -$23.1M -$3.2M
Diluted EPS -$106.08 -$82.85 -$13.55 -$13.89 -$1.50
Period Ending 2021-03-31 2022-03-31 2023-03-31 2024-03-31 2025-03-31
Balance Sheet
Current Assets $196.8M $207.6M $177.3M $80.9M $37.8M
Total Assets $200.4M $211M $180.1M $82.3M $38.6M
Current Liabilities $12.3M $16M $28.8M $31.5M $25.5M
Total Liabilities $13.7M $17M $127.1M $154.7M $128.7M
Total Equity $186.7M $194M $53M -$72.4M -$90.2M
Total Debt -- -- $95.1M $101.6M $105.5M
Trailing 12 Months Fiscal Quarters
Period Ending 2023-03-31 2024-03-31 2025-03-31 2024-03-31 2025-03-31
Cash Flow Statement
Cash Flow Operations -$155.3M -$120.4M -$66.4M -$17.7M -$12M
Cash From Investing -$19K -$20K -- -- --
Cash From Financing $120.4M $29M $23.2M $26.6M $13.2M
Free Cash Flow -$155.3M -$120.4M -$66.4M -$17.7M -$12M
BTAI
Sector
Market Cap
$9.4M
$32.3M
Price % of 52-Week High
6.21%
46.89%
Dividend Yield
0%
0%
Shareholder Yield
-251.68%
-0.66%
1-Year Price Total Return
-93.09%
-37.62%
Beta (5-Year)
-0.122
0.632
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

Technicals

8-day SMA
Sell
Level $1.77
200-day SMA
Sell
Level $5.32
Bollinger Bands (100)
Sell
Level 1.18 - 3.4
Chaikin Money Flow
Sell
Level -108.9M
20-day SMA
Buy
Level $1.52
Relative Strength Index (RSI14)
Buy
Level 52.94
ADX Line
Buy
Level 18.21
Williams %R
Neutral
Level -58.5106
50-day SMA
Buy
Level $1.62
MACD (12, 26)
Buy
Level 0.04
25-day Aroon Oscillator
Buy
Level 28
On Balance Volume
Neutral
Level 260.1M

Financial Scores

Sell
Altman Z-Score (Annual)
Level (-26.9529)
Sell
CA Score (Annual)
Level (-12.4551)
Sell
Beneish M-Score (Annual)
Level (0.2182)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (23.5197)
Buy
Piotroski F Score (Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)

Revenue Forecast

Earnings per Share Forecast

Company Profile

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company’s commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Stock Forecast FAQ

In the current month, BTAI has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The BTAI average analyst price target in the past 3 months is $27.33.

  • Where Will BioXcel Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that BioXcel Therapeutics share price will rise to $27.33 per share over the next 12 months.

  • What Do Analysts Say About BioXcel Therapeutics?

    Analysts are divided on their view about BioXcel Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that BioXcel Therapeutics is a Sell and believe this share price will drop from its current level to $16.00.

  • What Is BioXcel Therapeutics's Price Target?

    The price target for BioXcel Therapeutics over the next 1-year time period is forecast to be $27.33 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is BTAI A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for BioXcel Therapeutics is a Buy. 1 of 1 analysts rates the stock a Buy at this time.

  • How Can I Buy Shares Of BTAI?

    You can purchase shares of BioXcel Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase BioXcel Therapeutics shares.

  • What Is The BioXcel Therapeutics Share Price Today?

    BioXcel Therapeutics was last trading at $1.70 per share. This represents the most recent stock quote for BioXcel Therapeutics. Yesterday, BioXcel Therapeutics closed at $1.69 per share.

  • How To Buy BioXcel Therapeutics Stock Online?

    In order to purchase BioXcel Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Palantir Crash?
Will Palantir Crash?

AI and data analytics software major Palantir (NASDAQ:PLTR) has been…

Is Target’s Dividend Worth Buying?
Is Target’s Dividend Worth Buying?

Retail giant Target (NYSE:TGT) has been through an extremely volatile…

Where Will AST SpaceMobile Be In 5 Years?
Where Will AST SpaceMobile Be In 5 Years?

Ever tried to send a text from the Nevada desert…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 40x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 48x

Sell
37
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Sell
11
VEON alert for Jun 16

VEON [VEON] is up 4.61% over the past day.

Buy
79
DAVE alert for Jun 17

Dave [DAVE] is up 3.92% over the past day.

Buy
57
DAR alert for Jun 17

Darling Ingredients [DAR] is up 7.19% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock